Molbio Diagnostics is in the spotlight this week

Molbio Diagnostics is in the spotlight this week: the company reported its first-ever EBITDA and PAT profitability in FY27, driven by strong adoption of its Truenat diagnostic platform, while HDFC Mutual Fund acquired a 1.99% stake worth ₹302 crore, boosting investor confidence. 📊 Key Financial Updates Q1 FY27 Results (June 2026): Revenue: ₹411.48 crore (up from ₹100.47 crore YoY, though down 27.2% QoQ). EBITDA: ₹103.68 crore (vs. a ₹14.5 crore loss last year). PAT: ₹52.74 crore (vs. a ₹23.94 crore loss last year). Operating Margin: 20.4% (vs. -27.7% YoY). EPS: ₹5.21 (vs. -₹2.10 YoY). Revenue Mix: 75% from recurring test-kit sales, showing a shift to a sustainable, volume-led model. Market Cap: ~₹14,765 crore. Debt/Equity Ratio: 0.35 (low leverage). 📈 Stock Market Developments HDFC Mutual Fund Bulk Deal (1 Oct 2026): Bought 23 lakh shares (1.99% stake) at ₹1,315/share. Deal value: ₹302.45 crore. Seller: Business Excellence Trust III (Motilal Oswal PE), trimming its stake by ~2%. Share Price Movement: Rose 5% on 1 Oct 2026 after the deal. Current price: ~₹1,313–₹1,315. IPO (Aug 2026): ₹807 → Listing at ₹980. 52-week high: ₹1,686.80. Jefferies has a Buy rating with a target of ₹1,600 (27% upside from late September close).